Eagle Pharmaceut Stock Price, News & Analysis

Eagle Pharmaceuticals (Nasdaq: EGRX) reported strong financial results for Q4 2020 and the full year, highlighting a 36% increase in adjusted non-GAAP earnings year-over-year. Q4 revenue reached $49.9 million, driven by product sales growth of Ryanodex and Belrapzo. The company received a complete response letter from the FDA regarding its ANDA for vasopressin, but plans to resubmit by mid-2021. Full-year revenue was $187.8 million, down from $195.9 million in 2019, with net income of $12.0 million. Eagle intends to launch Pemfexy in February 2022 and remains focused on growth opportunities.

Eagle Pharmaceuticals (EGRX) will announce its Q4 and full-year 2020 financial results on March 2, 2021, before market opening. The event will feature a 90-minute conference call hosted by CEO Scott Tarriff and CFO Brian Cahill, starting at 8:30 a.m. ET. Investors can participate by calling toll-free or internationally. A replay will be available for a week post-call. Eagle focuses on developing innovative treatments, including RYANODEX®, BENDEKA®, and BELRAPZO®, aiming to address unmet medical needs across various conditions.

Eagle Pharmaceuticals (Nasdaq: EGRX) announced that the FDA has issued a complete response letter (CRL) for its ANDA for vasopressin. The Company has engaged in discussions with the FDA and plans an additional meeting within 30 days. Eagle intends to address the CRL's concerns and will conduct a short-duration study by mid-March, anticipating satisfactory results.

Additionally, litigation against Endo Par Innovation regarding vasopressin is set for July 7, 2021. Eagle remains optimistic about both the ANDA approval process and the patent litigation.

Eagle Pharmaceuticals, Inc. (EGRX) announced that the U.S. District Court for Delaware postponed the vasopressin trial with Endo Par Innovation, initially scheduled for February 1, 2021. A new trial date will be discussed in a court call. CEO Scott Tarriff expressed optimism, noting that Eagle's proposed product formulation differs from the patent claims, and they expect to gain 180 days of exclusivity post-trial. This litigation outcome may influence Eagle's market position and future product availability.

Eagle Pharmaceuticals (Nasdaq: EGRX) has announced a postponement of its vasopressin trial originally set for January 11, 2021, due to COVID-19 concerns. The trial will now begin remotely on February 1, 2021, and is expected to conclude by February 5, 2021. Eagle, a fully integrated pharmaceutical company, focuses on developing innovative medicines to improve patient lives, with products such as RYANODEX®, BENDEKA®, and BELRAPZO®. The company is engaged in research, clinical trials, and commercial activities aimed at addressing unmet medical needs.

Eagle Pharmaceuticals (Nasdaq: EGRX) announced that CEO Scott Tarriff and CFO Brian Cahill will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 4:30 p.m. EST. The presentation will be webcast live and archived for 30 days on the Company’s website under the Investors Section. Eagle is committed to developing innovative medicines, with commercialized products including RYANODEX®, BENDEKA®, and BELRAPZO®. For more information, visit www.eagleus.com.

Eagle Pharmaceuticals, Inc. (EGRX) announced the availability of its pre-recorded presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference. The presentation can be viewed via a link provided in the release and will also be available on Eagle's website for 30 days. Additionally, CEO Scott Tarriff and CFO Brian Cahill will engage in 1x1 meetings on December 1, 2020, which can be requested through Piper Sandler. The company remains focused on developing innovative medicines for critical care and oncology.

Eagle Pharmaceuticals (Nasdaq: EGRX) reported a strong financial performance for Q3 2020, with total revenue reaching $49.9 million, up from $41.1 million in Q3 2019. Net income for the quarter was $7.1 million, or $0.52 per share, compared to a net loss of $2.4 million last year. The company received FDA Priority Review for its vasopressin ANDA, added key executives to its leadership, and approved a $25 million share repurchase plan. Despite COVID-19 delays, Eagle remains optimistic about upcoming product launches and continued growth.

Eagle Pharmaceuticals (Nasdaq: EGRX) has appointed four new executives to strengthen its clinical and commercialization teams: Dr. Judi Ng-Cashin as EVP and Chief Medical Officer, John Kimmet as EVP of Oncology and Acute Care Marketing, Dr. Valentin R. Curt as SVP of Clinical Drug Development, and Dr. Gaozhong Zhu as SVP of Pharmaceutical Development. Brian Cahill has been promoted to Chief Financial Officer. The new leadership is expected to bolster Eagle's efforts in advancing its pipeline products, including EA-114, and support future growth strategies.